Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
NCT00441818
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
59
Enrollment
INDUSTRY
Sponsor class
Conditions
Hodgkin's Lymphoma
Interventions
DRUG:
TNX-650
Sponsor
Tanox